Cullinan shares positive clinical data for T cell engager programs CLN-978 and velinotamig

Cullinan Therapeutics reported encouraging Phase 1 clinical data for its CD19 and BCMA T cell engager programs targeting autoimmune diseases, with CLN-978 showing remissions in SLE and RA patients. The data supports advancement into additional indications and represents a potential paradigm shift in autoimmune disease treatment management.